Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Febrile neutropenia (FN) rates in metastatic hormone sensitive prostate cancer: the role of antibiotics as primary prophylaxis.
Pemberton L, Ng K, McGovern U, Macdonald A, Barot H, Galazi M, Wilson P, Wells P, Linch M, Alifrangis C, Shamash J. Pemberton L, et al. Among authors: alifrangis c. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):166-168. doi: 10.1038/s41391-020-0261-z. Epub 2020 Jul 24. Prostate Cancer Prostatic Dis. 2021. PMID: 32709977 No abstract available.
The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing.
Guo T, Wang Y, Jia J, Mao X, Stankiewicz E, Scandura G, Burke E, Xu L, Marzec J, Davies CR, Lu JJ, Rajan P, Grey A, Tipples K, Hines J, Kudahetti S, Oliver T, Powles T, Alifrangis C, Kohli M, Shaw G, Wang W, Feng N, Shamash J, Berney D, Wang L, Lu YJ. Guo T, et al. Among authors: alifrangis c. Front Cell Dev Biol. 2021 Jan 7;8:602493. doi: 10.3389/fcell.2020.602493. eCollection 2020. Front Cell Dev Biol. 2021. PMID: 33490068 Free PMC article.
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.
Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, Leone G, Xiang JZ, Wingate A, Tagawa S, Jayaram A, Linch M; PEACE Consortium; Jamal-Hanjani M, Swanton C, Rubin MA, Wyatt AW, Beltran H, Attard G, Demichelis F. Orlando F, et al. NAR Cancer. 2022 May 27;4(2):zcac016. doi: 10.1093/narcan/zcac016. eCollection 2022 Jun. NAR Cancer. 2022. PMID: 35664542 Free PMC article.
The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
Davies CR, Guo T, Burke E, Stankiewicz E, Xu L, Mao X, Scandura G, Rajan P, Tipples K, Alifrangis C, Wimalasingham AG, Galazi M, Crusz S, Powles T, Grey A, Oliver T, Kudahetti S, Shaw G, Berney D, Shamash J, Lu YJ. Davies CR, et al. Among authors: alifrangis c. Front Oncol. 2023 Jan 16;12:1060864. doi: 10.3389/fonc.2022.1060864. eCollection 2022. Front Oncol. 2023. PMID: 36727071 Free PMC article.
Treatment de-escalation for stage II seminoma.
Wood GE, Chamberlain F, Tran B, Conduit C, Liow E, Nicol DL, Shamash J, Alifrangis C, Rajan P. Wood GE, et al. Among authors: alifrangis c. Nat Rev Urol. 2023 Aug;20(8):502-512. doi: 10.1038/s41585-023-00727-0. Epub 2023 Mar 7. Nat Rev Urol. 2023. PMID: 36882564 Review.
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones.
Hasan AMM, Cremaschi P, Wetterskog D, Jayaram A, Wong SQ, Williams S, Pasam A, Trigos A, Trujillo B, Grist E, Friedrich S, Vainauskas O, Parry M, Ismail M, Devlies W, Wingate A, Linch M, Naceur-Lombardelli C; PEACE consortium; Swanton C, Jamal-Hanjani M, Lise S, Sandhu S, Attard G. Hasan AMM, et al. Nat Commun. 2023 Aug 10;14(1):4823. doi: 10.1038/s41467-023-40315-9. Nat Commun. 2023. PMID: 37563129 Free PMC article.
New drugs for prostate cancer.
Alifrangis C, O'Hanlon-Brown C, Tuthill M, Waxman J. Alifrangis C, et al. BJU Int. 2012 Jun;109(12):1801-6. doi: 10.1111/j.1464-410X.2011.10570.x. Epub 2011 Sep 20. BJU Int. 2012. PMID: 21933331 Review.
71 results